Chewable Tablet Adverse Events, Manufacturing Slips Prompt Guidance
This article was originally published in The Gold Sheet
Executive Summary
Chewable tablet manufacturers are overlooking quality attributes, leading to adverse events, according to an FDA draft guidance document. The agency recommends firms establish hardness, dissolution and disintegration of products early in manufacturing.
You may also be interested in...
Final FDA Guidance Delivers More Digestible Tablet Chewing Index
FDA’s final guidance on chewable tablets clarifies what is meant by a “chewing difficulty index” to assess product hardness. Properly formulating these products is key to avoiding quality failures such as choking patients.
Final FDA Guidance Delivers More Digestible Tablet Chewing Index
FDA’s final guidance on chewable tablets clarifies what is meant by a “chewing difficulty index” to assess product hardness. Properly formulating these products is key to avoiding quality failures such as choking patients.
Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: